Articles producció científica> Medicina i Cirurgia

Adjustment of eculizimab dosage pattern in patients with atypical hemolytic uremic síndrome with suboptimal response to standard treatment pattern

  • Identification data

    Identifier: imarina:6040509
    Handle: https://hdl.handle.net/20.500.11797/imarina6040509
    Authors:
    García Monteavaro C, Peralta Roselló C, Quiroga B, Baltar Martín JM, Castillo Eraso L, de Álvaro Moreno F, Martínez Vea A, Visus-Fernández de Manzanos MT.
    Abstract:
    In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV administration of 900 mg doses, followed by a maintenance phase with a 1,200 mg dose in the fifth week and every 14 ± 2 days thereafter. We present three patients with aHUS and suboptimal response to eculizumab treatment at the usual administration dosage who showed hematologic and renal improvements after an adjustment in the eculizumab treatment protocol.

  • Others:

    Author, as appears in the article.: García Monteavaro C, Peralta Roselló C, Quiroga B, Baltar Martín JM, Castillo Eraso L, de Álvaro Moreno F, Martínez Vea A, Visus-Fernández de Manzanos MT.
    Department: Medicina i Cirurgia
    URV's Author/s: Castillo Eraso, Norma Lorena / Martínez Vea, Alberto
    Abstract: In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV administration of 900 mg doses, followed by a maintenance phase with a 1,200 mg dose in the fifth week and every 14 ± 2 days thereafter. We present three patients with aHUS and suboptimal response to eculizumab treatment at the usual administration dosage who showed hematologic and renal improvements after an adjustment in the eculizumab treatment protocol.
    Thematic Areas: Nephrology
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: normalorena.castillo@urv.cat alberto.martinez@urv.cat
    Author identifier: 0000-0002-0819-8096
    Record's date: 2024-03-14
    Papper version: info:eu-repo/semantics/publishedVersion
    Papper original source: Case Rep Nephrol. 2016 7471082-7471082
    APA: García Monteavaro C, Peralta Roselló C, Quiroga B, Baltar Martín JM, Castillo Eraso L, de Álvaro Moreno F, Martínez Vea A, Visus-Fernández de Manzanos (2016). Adjustment of eculizimab dosage pattern in patients with atypical hemolytic uremic síndrome with suboptimal response to standard treatment pattern. Case Rep Nephrol, 2016(), 7471082-7471082. DOI: 10.1155/2016/7471082
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2016
    Publication Type: Journal Publications